Drugs / Sabizabulin

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT03752099 Jan 2019 → Mar 2023 castration-resistant prostate carcinoma Veru Inc. Terminated No outcome recorded
Phase 23 trials
Phase 2 NCT05079360 Mar 2023 → Mar 2024 breast cancer Veru Inc. Withdrawn No outcome recorded
Phase 2 NCT05008510 Dec 2021 → Jul 2022 triple-negative breast carcinoma Veru Inc. Withdrawn No outcome recorded
Phase 2 NCT04388826 Jun → Dec 2020 adult acute respiratory distress syndrome Veru Inc. Completed No outcome recorded
Phase 32 trials
Phase 3 NCT04844749 Jun 2021 → May 2023 castration-resistant prostate carcinoma, hormone-resistant prostate carcinoma Veru Inc. Terminated No outcome recorded
Phase 3 NCT04842747 May 2021 → Jul 2022 COVID-19 Veru Inc. Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Sabizabulin ClinicalTrials.gov intervention name — accepted as the source's own label NCT05008510
1

NCT05079360

Known as ABI-231 ChEMBL registry synonym — accepted as the source's own label CHEMBL2163631
Known as APP-111 ChEMBL registry synonym — accepted as the source's own label CHEMBL2163631
Known as SABIZABULIN HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL2163631
Known as Sabizatbulin hydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL2163631
Known as Veru-111 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04388826
3

NCT04844749

NCT04842747

NCT03752099

Known as VERU-111 hydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL2163631
Modality Small molecule CHEMBL2163631
Route Oral “VERU-111 will be administered orally” NCT03752099